Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RET
REST API REST API
Homo sapiens
RET is differentially expressed in 255 experiments: 113 organism parts: lung, prostate, ... (111 more);, 137 disease states: normal, colorectal adenocarcinoma, ... (135 more);, 71 cell types 256 cell lines 31 compound treatments and 71 other conditions.
Synonyms HSCR1, CDHR16, PTC, MTC1, MEN2A, MEN2B, RET51, CDHF12
Orthologs Ret (Mus musculus)   F1NL49_CHICK (Gallus gallus)   ret1 (Danio rerio)   F1MAG5_RAT (Rattus norvegicus)   RET (Bos taurus)   Ret (Drosophila melanogaster)   ret (Xenopus laevis)   A2SXS8_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, membrane, homophilic cell adhesion, MAPKKK cascade, protein tyrosine kinase activity, transmembrane receptor protein tyrosine kinase signaling pathway, posterior midgut development, ATP binding, receptor activity, nucleotide binding, protein serine/threonine kinase activity, transmembrane receptor protein tyrosine kinase activity, nervous system development, integral to membrane, signal transduction, positive regulation of transcription, DNA-dependent, calcium ion binding, protein kinase activity, embryonic epithelial tube formation, cellular response to retinoic acid, positive regulation of neuron projection development, neuron maturation, neural crest cell migration, ureteric bud development, enteric nervous system development, protein phosphorylation, positive regulation of metanephric glomerulus development
InterPro Term Prot_kinase_cat_dom, Cadherin, Tyr_kinase_Ret_rcpt, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession P07949, Q9UQV8, Q9UM90, Q8IZR8, Q9UE13, Q8NFE8, B4DGX8, Q9BTX6, C9JYL6, F5CNE9, F8TLS5, F8TLW0
Gene-Disease Assocation RENAL ADYSPLASIA, THYROID CARCINOMA, PAPILLARY, PHEOCHROMOCYTOMA, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B, COLORECTAL CANCER; CRC, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL; CCHS, THYROID CARCINOMA, FAMILIAL MEDULLARY; MTC, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA; MEN2A, HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1; HSCR1
Search EB-eye ENSG00000165731
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (28 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
MCF-7
3
E-GEOD-20081, E-GEOD-3529, E-GEOD-19639
BT-474
2
E-GEOD-3529, E-GEOD-5823
SW480
2
E-MEXP-1014, E-GEOD-18005
UACC812
2
E-MTAB-37, E-MTAB-62
primary culture
2
E-GEOD-2450, E-GEOD-1657
250 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, E-GEOD-20677, ... (37 experiments)

Factor Value U/D Experiments
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
1
2
E-TABM-145, E-TABM-130
embryonic stem cell
1
2
E-MEXP-930, E-GEOD-2248, E-GEOD-26672
adult native RPE from 78 y.o. donor
1
E-GEOD-18811
mesothelial cells
1
E-GEOD-21750
not specified
1
E-GEOD-18811
65 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-GEOD-16363, ... (50 experiments)

Factor Value U/D Experiments
Emery-Dreifuss muscular dystrophy
2
E-MTAB-62, E-GEOD-3307
chronic myelogenous leukemia
2
E-MTAB-62, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
myxoid liposarcoma
2
E-GEOD-6481, E-MTAB-62
neuroblastoma
2
E-MTAB-37, E-MTAB-62
131 more value(s).


Compound treatment

studied in E-GEOD-571, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (24 experiments)

Factor Value U/D Experiments
none
3
6
E-TABM-782, E-MEXP-1958, E-GEOD-4600, E-TABM-868, E-GEOD-412, ... (9 experiments)
hydroxyurea
1
E-GEOD-571
nocodazole
1
E-GEOD-571
17beta-estradiol
5
1
E-GEOD-4006
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
trans-hydroxytamoxifen
1
E-GEOD-4025
25 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-TABM-36, E-MEXP-1251, E-GEOD-4619, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-GEOD-2666, E-MTAB-62

Dfs follow up
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-19743, E-GEOD-8692, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-2292, E-TABM-868, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-MEXP-1446, E-GEOD-9764, E-MEXP-1103, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-GEOD-1926, E-GEOD-10433, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-MEXP-561 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-4600

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-10896, E-GEOD-17204

RNAi
studied in E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-1643, E-GEOD-12293, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561

Vehicle
studied in E-GEOD-5258

Processing time: 0.466 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM